Bristol Myers Squibb Psoriasis Drug Achieves Positive Phase 3 Results
By Matt Grossman
Bristol Myers Squibb Co.'s deucravacitinib drug for plaque
psoriasis achieved positive results in a pair of Phase 3 trials,
the drug maker said Friday.
In the studies, adults with moderate to severe plaque psoriasis
took 6 mg of the oral drug once a day. In both trials, more than
50% of patients achieved at least a 75% improvement from baseline
on a psoriasis metric after 16 weeks, compared with under 15% among
patients who got a placebo and 35% to 40% among patients who took
Otezla, another psoriasis drug. The share of patients with a
positive response improved after eight more weeks, and most of
those patients maintained their positive response in the 52nd week
In the studies, deucravacitinib also performed better than
placebo and Otezla in helping patients achieve sPGA 0/1 response,
another psoriasis metric based on a physician's assessment.
The drug was well tolerated, Bristol added.
Write to Matt Grossman at firstname.lastname@example.org
(END) Dow Jones Newswires
April 23, 2021 10:35 ET (14:35 GMT)
Copyright (c) 2021 Dow Jones & Company, Inc.